Becampanel

Drug Profile

Becampanel

Alternative Names: AMP 397; AMP 397A

Latest Information Update: 22 Jul 2010

Price : $50

At a glance

  • Originator Novartis
  • Class Antiepileptic drugs; Quinoxalines; Small molecules
  • Mechanism of Action AMPA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Epilepsy

Most Recent Events

  • 11 Nov 2002 Phase-II clinical trials in Epilepsy (PO)
  • 28 Oct 2002 Data presented at the 5th European Congress on Epileptology [5th ECE 2002]) have been added to the pharmacodynamics section
  • 14 Apr 2000 Phase-I clinical trials for Epilepsy in England (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top